There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on LHC Group (LHCG – Research Report), BridgeBio Pharma (BBIO – Research Report) and Relmada Therapeutics (RLMD – Research Report) with bullish sentiments.
LHC Group (LHCG)
Jefferies analyst Brian Tanquilut maintained a Buy rating on LHC Group on December 27 and set a price target of $200.00. The company’s shares closed last Tuesday at $137.90.
According to TipRanks.com, Tanquilut is a 4-star analyst with an average return of 7.4% and a 57.0% success rate. Tanquilut covers the Healthcare sector, focusing on stocks such as Oak Street Health, Surgery Partners, and Tenet Healthcare.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for LHC Group with a $181.45 average price target.
See today’s best-performing stocks on TipRanks >>
BridgeBio Pharma (BBIO)
Jefferies analyst Eun Yang maintained a Buy rating on BridgeBio Pharma on December 27 and set a price target of $28.00. The company’s shares closed last Wednesday at $13.10.
According to TipRanks.com, Yang is a 4-star analyst with an average return of 6.3% and a 50.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Taysha Gene Therapies, United Therapeutics, and Keros Therapeutics.
BridgeBio Pharma has an analyst consensus of Strong Buy, with a price target consensus of $27.11, a 101.9% upside from current levels. In a report released yesterday, Raymond James also maintained a Buy rating on the stock with a $17.00 price target.
Relmada Therapeutics (RLMD)
In a report issued on December 27, Andrew Tsai from Jefferies maintained a Buy rating on Relmada Therapeutics, with a price target of $75.00. The company’s shares closed last Tuesday at $22.36.
According to TipRanks.com, Tsai is a 3-star analyst with an average return of 11.5% and a 52.4% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, ATAI Life Sciences, and Marinus.
Currently, the analyst consensus on Relmada Therapeutics is a Strong Buy with an average price target of $55.67, which is a 149.0% upside from current levels. In a report issued on December 20, Leerink Partners also maintained a Buy rating on the stock with a $42.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LHCG: